NASDAQ:TCDATricida Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Tricida Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $16.97 -9.23 (-35.23 %) (As of 07/16/2020 10:50 AM ET) Add Compare Share Today's Range$16.33Now: $16.97▼$18.8050-Day Range$25.40MA: $26.48▼$27.5652-Week Range$18.02Now: $16.97▼$44.30Volume51,571 shsAverage Volume459,839 shsMarket Capitalization$847.65 millionP/E RatioN/ADividend YieldN/ABeta1.57 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Tricida, Inc., a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis. Tricida, Inc. was founded in 2013 and is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingTricida has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $50.00, Tricida has a potential upside of 200.3% from its current price of $16.65.Amount of Analyst CoverageTricida has received no research coverage in the past 90 days. Previous Next 1.9 Community Rank Outperform VotesTricida has received 98 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTricida has received 164 “underperform” votes. (Add your “underperform” vote.)Community SentimentTricida has received 62.60% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Tricida and other stocks. Vote “Outperform” if you believe TCDA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TCDA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTricida does not currently pay a dividend.Dividend GrowthTricida does not have a long track record of dividend growth. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tricida insiders have bought 55.76% more of their company's stock than they have sold. Specifically, they have bought $968,385.00 in company stock and sold $621,730.00 in company stock.Percentage Held by Insiders70.40% of the stock of Tricida is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions78.57% of the stock of Tricida is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Tricida are expected to grow in the coming year, from ($5.20) to ($3.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tricida is -3.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tricida is -3.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTricida has a P/B Ratio of 3.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.21 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TCDA Previous Symbol CUSIPN/A CIKN/A Webwww.tricida.com Phone415-429-7800Debt Debt-to-Equity Ratio0.34 Current Ratio5.56 Quick Ratio5.56Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.32 per share Price / Book3.19Profitability EPS (Most Recent Fiscal Year)($3.72) Net Income$-176,810,000.00 Net MarginsN/A Return on Equity-76.03% Return on Assets-57.35%Miscellaneous Employees76 Outstanding Shares49,950,000Market Cap$847.65 million Next Earnings Date8/13/2020 (Estimated) OptionableNot Optionable NASDAQ:TCDA Rates by TradingView Receive TCDA News and Ratings via Email Sign-up to receive the latest news and ratings for TCDA and its competitors with MarketBeat's FREE daily newsletter. Tricida (NASDAQ:TCDA) Frequently Asked Questions How has Tricida's stock been impacted by COVID-19 (Coronavirus)? Tricida's stock was trading at $28.05 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TCDA shares have decreased by 40.6% and is now trading at $16.65. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Tricida? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Tricida. When is Tricida's next earnings date? Tricida is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Tricida. How were Tricida's earnings last quarter? Tricida Inc (NASDAQ:TCDA) announced its quarterly earnings results on Thursday, May, 7th. The company reported ($1.49) EPS for the quarter, missing analysts' consensus estimates of ($1.41) by $0.08. View Tricida's earnings history. What price target have analysts set for TCDA? 2 equities research analysts have issued 1 year price targets for Tricida's stock. Their forecasts range from $50.00 to $50.00. On average, they anticipate Tricida's share price to reach $50.00 in the next year. This suggests a possible upside of 200.3% from the stock's current price. View analysts' price targets for Tricida. Has Tricida been receiving favorable news coverage? Headlines about TCDA stock have trended positive on Thursday, InfoTrie reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Tricida earned a news sentiment score of 2.1 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news about Tricida. Are investors shorting Tricida? Tricida saw a increase in short interest in June. As of June 30th, there was short interest totaling 4,740,000 shares, an increase of 5.3% from the June 15th total of 4,500,000 shares. Based on an average daily trading volume, of 334,200 shares, the short-interest ratio is currently 14.2 days. Approximately 12.3% of the shares of the stock are sold short. View Tricida's Current Options Chain. Who are some of Tricida's key competitors? Some companies that are related to Tricida include Arena Pharmaceuticals (ARNA), Alkermes (ALKS), Deciphera Pharmaceuticals (DCPH), Axsome Therapeutics (AXSM), CytoDyn (CYDY), Opko Health (OPK), Insmed (INSM), Amarin (AMRN), Taro Pharmaceutical Industries (TARO), Karuna Therapeutics (KRTX), TG Therapeutics (TGTX), Apellis Pharmaceuticals (APLS), Principia Biopharma (PRNB), Pacira Biosciences (PCRX) and SAGE Therapeutics (SAGE). View all competitors. What other stocks do shareholders of Tricida own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Gilead Sciences (GILD), Madrigal Pharmaceuticals (MDGL), Myovant Sciences (MYOV), Arena Pharmaceuticals (ARNA), Atara Biotherapeutics (ATRA), Biohaven Pharmaceutical (BHVN), Crispr Therapeutics (CRSP), CytomX Therapeutics (CTMX), Exelixis (EXEL) and Amicus Therapeutics (FOLD). Who are Tricida's key executives? Tricida's management team includes the following people: Dr. Gerrit Klaerner, Founder, Pres, CEO & Exec. Director (Age 48)Mr. Geoffrey M. Parker, CFO & Sr. VP (Age 54)Dr. Dawn Parsell Ph.D., Sr. VP of Clinical Devel. (Age 57)Steffen Pietzke, VP of Fin. & Chief Accounting OfficerDr. Wilhelm Stahl, CTO & Sr. VP (Age 59) When did Tricida IPO? (TCDA) raised $175 million in an initial public offering on Thursday, June 28th 2018. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen acted as the underwriters for the IPO. What is Tricida's stock symbol? Tricida trades on the NASDAQ under the ticker symbol "TCDA." How do I buy shares of Tricida? Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Tricida's stock price today? One share of TCDA stock can currently be purchased for approximately $16.65. How big of a company is Tricida? Tricida has a market capitalization of $831.67 million. The company earns $-176,810,000.00 in net income (profit) each year or ($3.72) on an earnings per share basis. Tricida employs 76 workers across the globe. What is Tricida's official website? The official website for Tricida is www.tricida.com. How can I contact Tricida? Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-429-7800 or via email at [email protected] This page was last updated on 7/16/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
